基于FOURIER试验结果的PCSK9抑制剂最新成本效益分析
Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
作者信息
Kazi Dhruv S, Penko Joanne, Coxson Pamela G, Moran Andrew E, Ollendorf Daniel A, Tice Jeffrey A, Bibbins-Domingo Kirsten
机构信息
Division of Cardiology, Zuckerberg San Francisco General Hospital, San Francisco, California.
Center for Vulnerable Populations, Zuckerberg San Francisco General Hospital, San Francisco, California.
出版信息
JAMA. 2017 Aug 22;318(8):748-750. doi: 10.1001/jama.2017.9924.
Abstract
This study uses the results of the FOURIER trial to assess the current cost-effectiveness of PCSK9 inhibitors over the lifetime analytic horizon for patients with atherosclerotic cardiovascular disease in the United States.
摘要
本研究利用FOURIER试验的结果，评估在美国患有动脉粥样硬化性心血管疾病的患者在终生分析范围内，PCSK9抑制剂目前的成本效益。
相似文献
1
Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.基于FOURIER试验结果的PCSK9抑制剂最新成本效益分析
JAMA. 2017 Aug 22;318(8):748-750. doi: 10.1001/jama.2017.9924.
2
Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.从医疗体系和私人支付方的角度来看依洛尤单抗的最新成本效益评估： FOURIER 试验得出的见解。
JAMA Cardiol. 2017 Dec 1;2(12):1369-1374. doi: 10.1001/jamacardio.2017.3655.
3
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.用于治疗高胆固醇水平的前蛋白转化酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂：有效性和价值。
JAMA Intern Med. 2016 Jan;176(1):107-8. doi: 10.1001/jamainternmed.2015.7248.
4
Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?前蛋白转化酶枯草溶菌素9型（PCSK9）抑制剂与心血管风险：对傅里叶试验的进一步分析是否提示降脂治疗靶点的变化？
High Blood Press Cardiovasc Prev. 2018 Mar;25(1):5-7. doi: 10.1007/s40292-017-0244-x. Epub 2018 Jan 5.
5
Do PCSK9 inhibitors reduce cardiovascular events?前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂能否降低心血管事件的发生？
Can Fam Physician. 2018 Sep;64(9):669.
6
Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.1090例高胆固醇血症患者尽管接受了最大耐受的低密度脂蛋白胆固醇降低治疗，但低密度脂蛋白胆固醇仍≥70mg/dL，他们被转诊至一家地区胆固醇治疗中心，符合alirocumab或evolocumab治疗的条件。
Vasc Health Risk Manag. 2017 Jul 6;13:247-253. doi: 10.2147/VHRM.S133690. eCollection 2017.
7
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.载脂蛋白 B 代谢途径抑制剂治疗杂合子型家族性高胆固醇血症或动脉粥样硬化性心血管疾病患者的成本效果分析。
JAMA. 2016 Aug 16;316(7):743-53. doi: 10.1001/jama.2016.11004.
8
Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol.涉及 PCSK9 抑制剂降低 LDL-胆固醇的结果、可及性和成本问题。
Drugs. 2018 Mar;78(3):287-291. doi: 10.1007/s40265-018-0867-9.
9
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.前蛋白转化酶枯草溶菌素/kexin 9型（PCSK9）抑制剂。一种用于治疗高胆固醇血症的新型药物类别。
Endocrinol Diabetes Nutr. 2017 Aug-Sep;64(7):341-344. doi: 10.1016/j.endinu.2017.04.005. Epub 2017 Jun 3.
10
Are PCSK9 Inhibitors Cost Effective?PCSK9 抑制剂是否具有成本效益？
Pharmacoeconomics. 2018 Sep;36(9):1031-1041. doi: 10.1007/s40273-018-0671-0.
引用本文的文献
1
Safety and Efficacy of Achieving Very Low LDL Cholesterol Concentrations with PCSK9 Inhibitors.使用前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂实现极低低密度脂蛋白胆固醇浓度的安全性和有效性。
J Clin Med. 2025 Jun 27;14(13):4562. doi: 10.3390/jcm14134562.
2
Efficacy and safety of combination therapy Ezetimibe 10/rosuvastatin 40 in Egyptian patients at very high risk of atherosclerotic cardiovascular disease.依折麦布10/瑞舒伐他汀40联合治疗对埃及动脉粥样硬化性心血管疾病极高风险患者的疗效和安全性
Egypt Heart J. 2025 Jun 11;77(1):59. doi: 10.1186/s43044-025-00655-x.
3
Clinical significance of low-density lipoprotein cholesterol percentage reduction and attained levels after percutaneous coronary intervention.经皮冠状动脉介入治疗后低密度脂蛋白胆固醇降低百分比及达到水平的临床意义。
CMAJ. 2025 Apr 27;197(16):E442-E452. doi: 10.1503/cmaj.241713.
4
PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention.PCSK9 抑制剂在一级和二级心血管预防中的应用。
Lipids Health Dis. 2024 Sep 10;23(1):290. doi: 10.1186/s12944-024-02283-x.
5
Lifelong prevention of atherosclerotic cardiovascular disease (ASCVD) through LDL-C control - Means and cost/benefit of sustained very low lifetime LDL-C targets.通过控制低密度脂蛋白胆固醇（LDL-C）实现动脉粥样硬化性心血管疾病（ASCVD）的终身预防——维持极低终身LDL-C目标的方法及成本效益
Am J Prev Cardiol. 2024 Aug 11;19:100720. doi: 10.1016/j.ajpc.2024.100720. eCollection 2024 Sep.
6
The Causal-Benefit Model to Prevent Cardiovascular Events.预防心血管事件的因果效益模型
JACC Adv. 2024 Jan 22;3(3):100825. doi: 10.1016/j.jacadv.2023.100825. eCollection 2024 Mar.
7
GLP-1 RA for cardiometabolic risk reduction in obesity - How do we best describe benefit and value?用于降低肥胖症患者心血管代谢风险的胰高血糖素样肽-1受体激动剂——我们如何最好地描述其益处和价值？
Am J Prev Cardiol. 2024 May 18;18:100682. doi: 10.1016/j.ajpc.2024.100682. eCollection 2024 Jun.
8
Is there a role for earlier use of combination therapy?早期使用联合疗法是否有作用？
Am J Prev Cardiol. 2024 Feb 15;17:100639. doi: 10.1016/j.ajpc.2024.100639. eCollection 2024 Mar.
9
Effects of a stepwise, structured LDL-C lowering strategy in patients post-acute coronary syndrome.急性冠状动脉综合征后患者逐步、结构化低密度脂蛋白胆固醇降低策略的效果
Neth Heart J. 2024 May;32(5):206-212. doi: 10.1007/s12471-023-01851-7. Epub 2024 Jan 26.
10
Review of Lipid-Lowering Therapy in Women from Reproductive to Postmenopausal Years.从生育期到绝经后期女性降脂治疗综述
Rev Cardiovasc Med. 2022;23(5). doi: 10.31083/j.rcm2305183. Epub 2022 May 19.
本文引用的文献
1
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.依洛尤单抗与心血管疾病患者的临床结局。
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
2
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.载脂蛋白 B 代谢途径抑制剂治疗杂合子型家族性高胆固醇血症或动脉粥样硬化性心血管疾病患者的成本效果分析。
JAMA. 2016 Aug 16;316(7):743-53. doi: 10.1001/jama.2016.11004.
Zotero 插件